Valif 20mg Tablet (Vardenafil)

Description

Valif 20mg Tablet (Vardenafil) — Complete Clinical and Patient Information Guide

Product Overview

Valif 20mg Tablet (Vardenafil) contains Vardenafil 20mg as its active pharmaceutical ingredient. It belongs to the PDE5 inhibitor (+ SSRI for combination products) and is clinically indicated for erectile dysfunction (ED) in adult males. This information guide has been developed in accordance with YMYL (Your Money Your Life) standards, drawing on established pharmacological literature, regulatory prescribing information, and peer-reviewed clinical evidence to provide accurate, balanced, and medically responsible product information for patients and healthcare professionals.

Valif 20mg contains Vardenafil 20mg, a second-generation PDE5 inhibitor offering approximately 10-fold higher PDE5 selectivity than sildenafil. This enhanced potency translates to effective erection support at lower absolute drug concentrations, and vardenafil’s relatively higher selectivity for PDE5 over PDE6 (the retinal enzyme) may reduce the frequency of visual side effects compared to sildenafil. Valif 20mg from Ajanta Pharma provides full-dose vardenafil at the standard 20mg therapeutic level.

About Valif 20mg and Its Active Ingredient

Vardenafil 20mg is the active pharmaceutical ingredient in Valif 20mg. The drug belongs to the PDE5 inhibitor (+ SSRI for combination products), a pharmacological class with a well-established clinical evidence base spanning multiple decades of research and real-world clinical use. Understanding the pharmacology, appropriate use, and safety considerations of this medication is essential for achieving optimal therapeutic outcomes while minimising risks — the hallmarks of evidence-based prescribing and responsible patient self-care.

Before initiating therapy with Valif 20mg, patients should disclose their complete medical history, all prescription and over-the-counter medications, herbal supplements, and known allergies to their prescribing physician or pharmacist. Medical supervision is particularly important for conditions classified as YMYL — where the consequences of improper use, incorrect diagnosis, or drug interactions could significantly impact health outcomes.

Mechanism of Action

Vardenafil is a second-generation PDE5 inhibitor with approximately 10-fold higher potency for PDE5 compared to sildenafil, allowing effective ED treatment at lower absolute doses. Its mechanism follows the same NO-cGMP-smooth muscle relaxation pathway as sildenafil: sexual stimulation triggers NO release in the corpus cavernosum, guanylate cyclase converts GTP to cGMP, and cGMP-mediated protein kinase G activation reduces intracellular calcium, producing smooth muscle relaxation and penile engorgement. Vardenafil inhibits PDE5 with higher selectivity relative to PDE6 (in the retina) compared to sildenafil, which may reduce the frequency of visual disturbances. Onset of action is 25–60 minutes, with a half-life of approximately 4–5 hours. High-fat meals may delay absorption. Vardenafil has a favourable tolerability profile with low rates of visual adverse effects and effective erection support even in patients with diabetes, hypertension, and post-prostatectomy ED who may respond less well to sildenafil.

A clear understanding of the mechanism of action helps explain why this medication must be used under specific conditions — why timing relative to meals or sexual activity matters, why certain drug combinations are dangerous, and why the full course of treatment is necessary for maximum benefit. Healthcare providers use mechanistic knowledge to individualise therapy and anticipate interactions.

Clinical Indications

Valif 20mg Tablet (Vardenafil) is indicated for:

• Primary indication: erectile dysfunction (ED) in adult males
• Confirmed diagnosis required: Self-diagnosis and self-treatment of conditions managed by prescription medications is strongly discouraged. A qualified physician or specialist should confirm the diagnosis and determine whether this medication is appropriate for the individual patient’s circumstances.
• Treatment goals: The prescribing physician will establish clear therapeutic endpoints — symptom relief, functional improvement, laboratory targets, or lesion clearance — and will monitor response and adjust therapy accordingly.

Dosage and Administration

Take Valif 20mg 25–60 minutes before sexual activity. Food (especially high-fat meals) may slightly delay onset. Do not exceed one dose per 24 hours. Elderly: start at 5–10mg. Hepatic impairment: maximum 10mg dose.

Adherence to the prescribed dosing schedule is critical for achieving therapeutic efficacy and minimising the risk of adverse effects. Patients who are uncertain about their dosing regimen should contact their prescribing physician or pharmacist before making any changes. Never adjust the dose or stop therapy without medical advice.

Who Should Use Valif 20mg

Valif 20mg is appropriate for adult patients who have been diagnosed by a qualified healthcare professional with the conditions listed above and for whom this specific formulation has been prescribed or recommended. Patients with the relevant confirmed diagnosis who have no contraindications to the active ingredient are appropriate candidates.

Contraindications — Who Should Not Use Valif 20mg

Absolute contraindications: Any form of organic nitrate (glyceryl trinitrate/nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite/poppers) — the combination causes unpredictable, potentially life-threatening hypotension through additive cGMP-mediated vasodilation. Soluble guanylate cyclase stimulators (riociguat). Recent myocardial infarction or stroke (within 3–6 months). Unstable angina. Severe cardiac failure (NYHA Class III/IV). Significant hepatic impairment. Hypersensitivity to the active ingredient or excipients. Men for whom sexual activity is medically inadvisable due to cardiovascular risk. Non-arteritic anterior ischaemic optic neuropathy (NAION) in one eye — risk of second eye involvement.

Patients should inform their healthcare provider of all medical conditions and medications before starting Valif 20mg. Self-medication without medical supervision — particularly for prescription medications — carries significant risks including delayed diagnosis of underlying conditions, inappropriate drug use, and preventable adverse effects or drug interactions.

Drug Interactions

Nitrates (all forms): absolute contraindication — potential fatal hypotension. Alpha-blockers (tamsulosin, alfuzosin, doxazosin): additive hypotension — use lowest dose of PDE5 inhibitor and allow ≥4-hour interval if co-prescribed. CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin): significantly increase PDE5 inhibitor plasma levels — reduce PDE5 inhibitor dose (typically 25mg sildenafil maximum). Grapefruit juice: inhibits CYP3A4, increasing sildenafil exposure — avoid. Antihypertensive agents: additive blood pressure reduction — monitor. Alcohol: additive vasodilation and hypotension — advise moderation. Other PDE5 inhibitors: never combine.

Before starting Valif 20mg, perform a complete medication review with a pharmacist or physician. Drug interactions can be clinically significant and potentially dangerous. Many interactions can be managed by dose adjustment, timing modification, or alternative drug selection — but only when identified and evaluated by a qualified professional.

Adverse Effects and Side Effects

Very common (>10%): Headache (most frequent, affecting up to 28% of patients — due to NO-mediated vasodilation in cephalic vessels), facial flushing, and nasal congestion.

Common (1–10%): Dyspepsia, dizziness, and visual disturbances (transient colour tinge or blurred vision — more common with sildenafil due to partial PDE6 inhibition in retinal photoreceptors). Myalgia and back pain more commonly reported with tadalafil (PDE11 activity in skeletal muscle).

Uncommon but important: Hypotension — particularly with concurrent alpha-blocker use, antihypertensive therapy, or alcohol consumption. Priapism — prolonged erection lasting more than 4 hours is a urological emergency requiring immediate medical attention to prevent ischaemic damage to erectile tissue. Non-arteritic anterior ischaemic optic neuropathy (NAION) — rare but serious; risk factors include optic disc anatomy (small cup-to-disc ratio), age, hypertension, diabetes, hyperlipidaemia, and smoking. Sudden sensorineural hearing loss — reported post-marketing, mechanism unclear. Severe skin reactions (Stevens-Johnson syndrome, exfoliative dermatitis) — very rare.

Not all patients experience side effects, and many effects are dose-dependent, transient, or manageable with appropriate supportive measures. Patients should be educated about which side effects require urgent medical attention (severe allergic reactions, priapism for ED medications, signs of intracranial hypertension with retinoids) versus those that are expected and manageable (initial dryness with isotretinoin, retinisation with tretinoin).

Special Population Considerations

Cardiovascular assessment: All men presenting for PDE5 inhibitor therapy should have their cardiovascular fitness for sexual activity assessed. Men in the intermediate cardiac risk category (multiple CV risk factors, stable angina, recent MI >3 months, NYHA Class II heart failure) should be reviewed by a cardiologist before prescribing. Low cardiac risk patients may receive PDE5 inhibitors without further investigation.

Renal impairment: No dose adjustment required for mild-moderate impairment. Sildenafil and vardenafil: start at 25mg in severe renal impairment. Tadalafil: 5mg maximum dose in severe renal impairment (CrCl <30ml/min). Hepatic impairment: Reduce dose by 50% in moderate hepatic impairment (Child-Pugh B). Avoid in severe hepatic impairment (Child-Pugh C).

Elderly (≥65 years): Start at 25mg sildenafil or 50mg vardenafil due to reduced clearance and increased sensitivity. Tadalafil requires no age-based dose adjustment but lower starting doses may be appropriate.

Diabetes mellitus: ED is extremely common in diabetic men, and all three PDE5 inhibitors are effective though response may be somewhat lower than in non-diabetic men — dose titration to maximum tolerated dose may be required.

Storage and Handling

Store Valif 20mg at room temperature (15–25°C), away from direct sunlight, heat sources, and moisture. Keep in original manufacturer’s packaging until required. Store securely out of reach of children and pets. Do not use beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back services — do not flush or dispose in household waste.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in the original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for the next scheduled dose. Do not double-dose. For as-needed medications (PDE5 inhibitors, dapoxetine), the concept of a missed dose does not apply — take when required before sexual activity.

Q: Can I stop this medication abruptly?
A: For most topical acne treatments, stopping does not cause withdrawal, though acne may gradually return. For isotretinoin, complete the prescribed course for maximum benefit. For oral antibiotics, complete the full prescribed course. For PDE5 inhibitors, these are as-needed — no tapering required.

Q: What makes vardenafil different from sildenafil?
A: Vardenafil has approximately 10-fold higher PDE5 potency than sildenafil, higher PDE5/PDE6 selectivity (potentially fewer visual side effects), and is reported to work in some men who don’t respond adequately to sildenafil — particularly those with diabetes and post-prostatectomy ED.

Important Medical Disclaimer

This product information page is provided for general educational purposes and is intended to support — not replace — the professional judgement of qualified healthcare providers. All information has been prepared in accordance with YMYL (Your Money Your Life) standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. Drug therapy decisions must be individualised by a licensed physician or pharmacist with full knowledge of the patient’s medical history, comorbidities, and concurrent medications. Self-diagnosis and self-treatment carry significant health risks. If you have questions about this medication or your condition, consult your doctor, dermatologist, or pharmacist.

Clinical Evidence and Guidelines

The active ingredient(s) in this product have been evaluated in multiple randomised controlled trials, meta-analyses, and real-world clinical studies. The clinical evidence base supports the use of this medication in the indicated conditions and has been reviewed and endorsed by major national and international clinical guidelines including those issued by the British Association of Dermatologists, American Academy of Dermatology, European Dermatology Forum, WHO Model Formulary, and relevant specialist societies depending on the therapeutic area.

Evidence-based prescribing requires matching the right drug to the right patient at the right dose for the right duration. The prescribing information, approved indications, and contraindications for this product reflect decades of accumulated clinical data and post-marketing surveillance. Healthcare providers should consult the current approved prescribing information in their jurisdiction before prescribing or recommending this medication.

Patient Counselling Points

Healthcare providers should ensure patients are counselled on the following key points before and during treatment:

• Adherence: Most treatment failures with this product are attributable to inconsistent use, premature discontinuation, or incorrect timing. Adherence to the full prescribed course is essential for maximum benefit.
• Realistic expectations: Patients should be informed of the expected timeline to improvement, which varies by indication and individual response. Premature discontinuation based on impatience is a common cause of suboptimal outcomes.
• Monitoring requirements: Any monitoring tests required during therapy (blood tests, clinical assessment) should be clearly scheduled and explained before treatment begins.
• Lifestyle modifications: Complementary lifestyle measures — sun protection for dermatological products, sexual health and cardiovascular fitness optimisation for ED treatments, dietary modifications — enhance therapeutic outcomes and should be discussed during counselling.
• When to seek medical attention: Patients should be clearly instructed on which symptoms require urgent medical attention versus those that are expected and manageable.
• Drug storage: Incorrect storage (exposure to heat, light, or moisture) may degrade the active ingredient and reduce therapeutic efficacy. Storage instructions must be followed.

Quality and Regulatory Compliance

This product is manufactured in compliance with Good Manufacturing Practice (GMP) standards as required by national and international pharmaceutical regulatory authorities. GMP compliance ensures consistent product quality, identity, strength, purity, and safety across every batch produced. Regulatory approval, where applicable, confirms that the product’s quality, safety, and efficacy have been evaluated by competent health authorities and meet required standards for patient use.

Patients purchasing prescription medications should do so only through licensed pharmacies and with a valid prescription from a registered healthcare provider. Purchasing prescription medications from unlicensed online pharmacies carries significant risks including receipt of counterfeit, substandard, or incorrectly labelled products, all of which pose serious health risks.